Welcome to LookChem.com Sign In|Join Free

CAS

  • or

188440-21-3

Post Buying Request

188440-21-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

188440-21-3 Usage

Description

3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is a sulfonyl chloride derivative with the molecular formula C7H4BrCl2O2S. It is a highly reactive and electrophilic compound that serves as a versatile intermediate in the preparation of a wide range of functionalized organic compounds.

Uses

Used in Pharmaceutical Industry:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a reagent in organic synthesis for the development of new pharmaceutical compounds. Its reactivity and electrophilic nature make it an important building block for the synthesis of biologically active molecules with potential therapeutic applications.
Used in Agrochemical Industry:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a precursor in the synthesis of agrochemicals. Its versatility and reactivity contribute to the development of new compounds with potential applications in agriculture, such as pesticides and herbicides.
Used in Specialty Chemicals Production:
3-Bromomethyl-2,4-dichlorobenzenesulfonyl chloride is used as a precursor for the production of various specialty chemicals. Its unique structure and reactivity enable the creation of novel compounds with specific properties for use in different industries, such as dyes, polymers, and coatings.

Check Digit Verification of cas no

The CAS Registry Mumber 188440-21-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,8,4,4 and 0 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 188440-21:
(8*1)+(7*8)+(6*8)+(5*4)+(4*4)+(3*0)+(2*2)+(1*1)=153
153 % 10 = 3
So 188440-21-3 is a valid CAS Registry Number.

188440-21-3Downstream Products

188440-21-3Relevant articles and documents

Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists

Amaudrut, Jér?me,Argiriadi, Maria A.,Barth, Martine,Breinlinger, Eric C.,Bressac, Didier,Broqua, Pierre,Calderwood, David J.,Chatar, Mohamed,Cusack, Kevin P.,Gauld, Stephen B.,Jacquet, Sébastien,Kamath, Rajesh V.,Kort, Michael E.,Lepais, Valérie,Luccarini, Jean-Michel,Masson, Philippe,Montalbetti, Christian,Mounier, Laurent,Potin, Dominique,Poupardin, Olivia,Rouaud, Sylvie,Spitzer, Luc,Wallace, Craig D.

, p. 1799 - 1806 (2019/05/17)

A high-throughput screen against Inventiva's compound library using a Gal4/RORγ-LBD luciferase reporter gene assay led to the discovery of a new series of quinoline sulphonamides as RORγ inhibitors, eventually giving rise to a lead compound having an inte

NON-PEPTIDE BRADYKININ ANTAGONISTS AND PHARMACEUTICAL COMPOSITIONS THEREFROM

-

Page/Page column 9-10, (2010/11/08)

Non-peptide compounds having activity as selective antagonists of bradykinin (BK) B2 receptor. The compounds are chemically characterized by the presence of an amino acid alpha substituted with a cyclic group and by a tetraalkylammonium group.

Benzenesulfonamide derivatives as bradykinin antagonists

-

, (2008/06/13)

PCT No. PCT/FR96/01262 Sec. 371 Date Apr. 7, 1997 Sec. 102(e) Date Apr. 7, 1997 PCT Filed Aug. 7, 1996 PCT Pub. No. WO97/07115 PCT Pub. Date Feb. 27, 1997The present invention relates to compounds selected from the group consisting of the compounds of formula (I): X is a halogen atom, A is -CH2-, -CH(OH)-, -CH(NH-COCH3)- or S, R is H, CO2H, CO2-B-R1 or CO-N(R2)-B-R1, B is linear, branched or cyclic C1-C10-alkylene, R1 is H, CH2OH, CH2-O-CH3, CH2-NR3R4 or phenyl, R2 is H or C1-C4-alkyl, R3 is H or linear, branched or cyclic C1-C10-alkyl, R4 is H or linear or branched C1-C10-alkyl, it being possible for NR3R4 to be a saturated heterocyclic radical having from 5 to 8 ring members and containing at least one nitrogen atom, and the carbon carrying the substituent R, when Q is saturated, can be of indeterminate (R,S) configuration or of determinate (R) or (S) configuration; and their addition salts. It further relates to their use in therapeutics, especially for pathological conditions involving bradykinin.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 188440-21-3